Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer. The M&M Study.

February 18, 2021

Protocol: Wake Forest WF-1806


Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!


  1. Older adults (age ≥ 60y) with either: 1. Newly diagnosed metastatic CRC or 2. Newly recognized metastatic recurrence or CRC greater than 1 year from completion of treatment for non-metastatic CRC.
  2. Planning to undergo immunotherapy and/or 5/FU based chemotherapy as first line of treatment.  5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan; +/- immunmotherapy. Capecitabine is also acceptable.
  3. Life expectancy greater than or equal to 6 months.
  4. Patient eligibility is not dependent on BMI or weight.  Patients with a significant (+- > 10%) body weight change in the previous 12 months are eligible for this study.


  1. Patients enrolled in hospice.
  2. Prior systemic chemotherapy for metastatic colorectal cancer (acceptable if adjuvant chemotherapy completed greater to or equal to 12 months prior disease recurrence).
  3. Patients may not be receiving any other investigational agents.
  4. No untreated brain metastases. Patients with treated brain metastases are eligible.
  5. Patients on or planned to undergo radiation therapy in the near future.

Genesys Hurley Cancer Institute

302 Kensington Avenue (Print a Map)
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium


Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.